How  	How  	 WRB	O
HCV  	HCV  	 NNP	B-NP
has  	has  	 VBZ	O
changed  	changed  	 VBN	O
the  	the  	 DT	O
approach  	approach  	 NN	O
to  	to  	 TO	O
mixed  	mixed  	 JJ	O
cryoglobulinemia  	cryoglobulinemia  	 JJ	B-NP
Mixed  	Mixed  	 JJ	I-NP
cryoglobulinemia  	cryoglobulinemia  	 NN	I-NP
is  	is  	 VBZ	O
a  	a  	 DT	O
systemic  	systemic  	 JJ	B-NP
disease  	disease  	 NN	I-NP
due  	due  	 JJ	O
to  	to  	 TO	O
a  	a  	 DT	O
small  	small  	 JJ	O
vessel  	vessel  	 NN	B-NP
immune-complex  	immune-complex  	 JJ	I-NP
mediated  	mediated  	 JJ	O
vasculitis 	vasculitis 	 NN	B-NP
.  	.  	 .	O
The  	The  	 DT	O
discovery  	discovery  	 NN	O
of  	of  	 IN	O
a  	a  	 DT	O
viral  	viral  	 JJ	B-NP
origin  	origin  	 NN	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
disease  	disease  	 NN	O
has  	has  	 VBZ	O
launched  	launched  	 VBN	O
a  	a  	 DT	O
great  	great  	 JJ	O
expectancy  	expectancy  	 NN	O
among  	among  	 IN	O
researchers  	researchers  	 NNS	O
and  	and  	 CC	O
the  	the  	 DT	O
years  	years  	 NNS	O
after  	after  	 IN	O
this  	this  	 DT	O
finding  	finding  	 NN	O
have  	have  	 VBP	O
been  	been  	 VBN	O
characterized  	characterized  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
effort  	effort  	 NN	O
to  	to  	 TO	O
reach  	reach  	 VB	O
viral  	viral  	 JJ	B-NP
eradication  	eradication  	 NN	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
hope  	hope  	 NN	O
of  	of  	 IN	O
obtaining  	obtaining  	 VBG	B-NP
disease  	disease  	 NN	I-NP
remission 	remission 	 NN	I-NP
.  	.  	 .	O
Moreover 	Moreover 	 RB	O
,  	,  	 ,	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
immunosuppressives  	immunosuppressives  	 NN	B-NP
has  	has  	 VBZ	O
been  	been  	 VBN	O
discouraged  	discouraged  	 VBN	O
for  	for  	 IN	O
many  	many  	 JJ	O
years  	years  	 NNS	O
as  	as  	 IN	O
they  	they  	 PRP	O
could  	could  	 MD	O
favour  	favour  	 VB	O
viral  	viral  	 JJ	B-NP
replication 	replication 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
HCV  	HCV  	 NNP	B-NP
infection  	infection  	 NN	O
has  	has  	 VBZ	O
represented  	represented  	 VBN	O
a  	a  	 DT	O
contraindication  	contraindication  	 NN	B-NP
to  	to  	 TO	O
the  	the  	 DT	O
more  	more  	 RBR	O
recent  	recent  	 JJ	O
biological  	biological  	 JJ	B-NP
drugs  	drugs  	 NNS	I-NP
directed  	directed  	 VBN	O
against  	against  	 IN	O
cytokines 	cytokines 	 NN	B-NP
.  	.  	 .	O
The  	The  	 DT	O
trials  	trials  	 NNS	O
with  	with  	 IN	O
antiviral  	antiviral  	 JJ	B-NP
agents  	agents  	 NNS	I-NP
in  	in  	 IN	O
this  	this  	 DT	O
disorder 	disorder 	 NN	O
,  	,  	 ,	O
however 	however 	 RB	O
,  	,  	 ,	O
has  	has  	 VBZ	O
not  	not  	 RB	O
met  	met  	 VBD	O
the  	the  	 DT	O
expectations 	expectations 	 NNS	B-NP
,  	,  	 ,	O
especially  	especially  	 RB	O
when  	when  	 WRB	O
challenged  	challenged  	 VBN	O
with  	with  	 IN	O
some  	some  	 DT	O
of  	of  	 IN	O
the  	the  	 DT	O
most  	most  	 RBS	O
severe  	severe  	 JJ	O
complications  	complications  	 NNS	B-NP
of  	of  	 IN	O
the  	the  	 DT	O
disease 	disease 	 NN	O
;  	;  	 :	O
moreover 	moreover 	 RB	O
,  	,  	 ,	O
these  	these  	 DT	O
medications  	medications  	 NN	O
were  	were  	 VBD	O
not  	not  	 RB	O
devoid  	devoid  	 VBN	O
of  	of  	 IN	O
unexpected  	unexpected  	 JJ	O
side  	side  	 NN	B-NP
effects 	effects 	 NNS	I-NP
,  	,  	 ,	O
such  	such  	 JJ	O
as  	as  	 IN	O
the  	the  	 DT	O
occurrence  	occurrence  	 NN	O
of  	of  	 IN	O
peripheral  	peripheral  	 JJ	B-NP
neuropathies 	neuropathies 	 NN	I-NP
.  	.  	 .	O
Since  	Since  	 IN	O
lymphoproliferation  	lymphoproliferation  	 NN	B-NP
is  	is  	 VBZ	O
one  	one  	 CD	O
of  	of  	 IN	O
the  	the  	 DT	O
features  	features  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
disease 	disease 	 NN	O
,  	,  	 ,	O
this  	this  	 DT	O
has  	has  	 VBZ	O
focused  	focused  	 VBN	O
the  	the  	 DT	O
attention  	attention  	 NN	O
of  	of  	 IN	O
investigators  	investigators  	 NNS	B-NP
on  	on  	 IN	O
the  	the  	 DT	O
potential  	potential  	 JJ	B-NP
benefit  	benefit  	 NN	I-NP
of  	of  	 IN	O
newly  	newly  	 RB	O
targeted  	targeted  	 VBN	B-NP
therapies  	therapies  	 NNS	I-NP
specifically  	specifically  	 RB	O
directed  	directed  	 VBN	O
against  	against  	 IN	O
B-lymphocytes  	B-lymphocytes  	 NNP	B-NP
( 	( 	 -LRB-	O
such  	such  	 JJ	O
as  	as  	 IN	O
rituximab 	rituximab 	 CD	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
Preliminary  	Preliminary  	 JJ	B-NP
results  	results  	 NNS	I-NP
on  	on  	 IN	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
these  	these  	 DT	O
medications  	medications  	 NNS	O
are  	are  	 VBP	O
promising 	promising 	 VBG	O
.  	.  	 .	O
Furthermore 	Furthermore 	 RB	O
,  	,  	 ,	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
biological  	biological  	 JJ	B-NP
agents  	agents  	 NNS	I-NP
in  	in  	 IN	O
small  	small  	 JJ	O
open  	open  	 JJ	O
trials  	trials  	 NNS	O
in  	in  	 IN	O
HCV  	HCV  	 NNP	B-NP
positive  	positive  	 JJ	O
arthritis  	arthritis  	 NN	O
patients  	patients  	 NNS	O
has  	has  	 VBZ	O
demonstrated  	demonstrated  	 VBN	O
an  	an  	 DT	O
acceptable  	acceptable  	 JJ	O
safety  	safety  	 NN	O
profile 	profile 	 NN	O
.  	.  	 .	O
All  	All  	 PDT	O
these  	these  	 DT	O
empirical  	empirical  	 JJ	B-NP
observations  	observations  	 NNS	I-NP
should  	should  	 MD	O
probably  	probably  	 RB	O
induce  	induce  	 VB	O
the  	the  	 DT	O
scientific  	scientific  	 JJ	B-NP
community  	community  	 NN	I-NP
to  	to  	 TO	O
reconsider  	reconsider  	 VB	O
the  	the  	 DT	O
therapeutical  	therapeutical  	 JJ	B-NP
approach  	approach  	 NN	I-NP
to  	to  	 TO	O
HCV-related  	HCV-related  	 JJ	B-NP
mixed  	mixed  	 JJ	O
cryoglobulinemia 	cryoglobulinemia 	 NN	B-NP
.  	.  	 .	O
Indeed 	Indeed 	 RB	O
,  	,  	 ,	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
aggressive  	aggressive  	 JJ	B-NP
chemotherapy  	chemotherapy  	 JJ	I-NP
treatments  	treatments  	 NNS	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
era  	era  	 NN	O
preceding  	preceding  	 VBG	O
HCV  	HCV  	 NNP	B-NP
discovery  	discovery  	 NN	O
has  	has  	 VBZ	O
not  	not  	 RB	O
been  	been  	 VBN	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
significant  	significant  	 JJ	O
liver  	liver  	 NN	O
toxicities  	toxicities  	 NNS	O
and  	and  	 CC	O
standard  	standard  	 JJ	O
chemotherapy  	chemotherapy  	 NN	O
during  	during  	 IN	O
HCV-related  	HCV-related  	 JJ	B-NP
lymphoma  	lymphoma  	 NN	I-NP
carried  	carried  	 VBD	O
out  	out  	 RP	O
a  	a  	 DT	O
unexpected  	unexpected  	 JJ	O
low  	low  	 JJ	O
rate  	rate  	 NN	O
of  	of  	 IN	O
severe  	severe  	 JJ	O
liver  	liver  	 NN	O
damage 	damage 	 NN	O
.  	.  	 .	O
Future  	Future  	 JJ	O
efforts  	efforts  	 NNS	O
should  	should  	 MD	O
probably  	probably  	 RB	O
focus  	focus  	 VB	O
on  	on  	 IN	O
the  	the  	 DT	O
potential  	potential  	 JJ	B-NP
benefit  	benefit  	 NN	I-NP
of  	of  	 IN	I-NP
a  	a  	 DT	I-NP
multi-step 	multi-step 	 JJ	I-NP
,  	,  	 ,	O
combined  	combined  	 VBN	O
anti-viral  	anti-viral  	 JJ	B-NP
and  	and  	 CC	O
cytotoxic  	cytotoxic  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
( 	( 	 -LRB-	O
both  	both  	 DT	O
with  	with  	 IN	O
standard  	standard  	 JJ	O
regimens  	regimens  	 NN	O
and  	and  	 CC	O
new  	new  	 JJ	O
medications 	medications 	 NN	O
) 	) 	 -RRB-	O
.  	.  	 .	O
